2seventy bio, Inc. (TSVT) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)
November 12, 2024 12:52 PM ESTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $2.00 price target on 2Seventy Bio Inc. (NASDAQ: TSVT).
The analyst comments "TSVT reported 3Q US Abecma sales of $77mn (as reported by partner BMY) vs. GSe/Visible Alpha consensus of $70mn/$70mn, with Abecma profit-share of $11mn (vs. GSe/consesnus of $7mn/$11mn); GAAP EPS of ($0.19) was in line with consensus of ($0.19) (vs. GSe of ($0.34); Exhibit 1). While 3Q Abecma... More



